In this article, we discuss 5 high-growth micro-cap stocks to buy. To read the detailed analysis and past performance of micro-cap stocks, go directly to the 11 High Growth Micro-cap Stocks to Buy.
5. Blade Air Mobility, Inc. (NASDAQ:BLDE)
Latest QTR YoY Revenue Growth: 56.2%
Number of Hedge Fund Holders: 10
Blade Air Mobility, Inc. (NASDAQ:BLDE) is a company that is engaged in the arrangement of charter and by-the-seat flights of helicopters, jets, turboprops, and amphibious seaplanes.
On November 8, Blade Air Mobility, Inc. (NASDAQ:BLDE) announced its Q3 GAAP EPS of $0.00 and revenue of $71.4 million, which increased 56.2% year-over-year (YoY).
3 Wall Street analysts covered Blade Air Mobility, Inc. (NASDAQ:BLDE) over the last three months, and all kept a Buy rating on the stock. The average price target of $8.17 had an upside of 138.89% as of the December 22 market close.
In the third quarter, 10 hedge funds were bullish on Blade Air Mobility, Inc. (NASDAQ:BLDE)’s stock at a total stake value of $21.54 million.
Follow Blade Air Mobility Inc. (NASDAQ:BLDE)
Follow Blade Air Mobility Inc. (NASDAQ:BLDE)
4. Ouster, Inc. (NYSE:OUST)
Latest QTR YoY Revenue Growth: 98.3%
Number of Hedge Fund Holders: 13
Ouster, Inc. (NYSE:OUST) is a California-based company that develops and provides high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions.
According to Insider Monkey’s database, in the third quarter, 13 hedge funds held a stake in Ouster, Inc. (NYSE:OUST)’s stock at a combined hedge fund value of $14.7 million.
On November 9, Ouster, Inc. (NYSE:OUST) announced its third-quarter earnings result with a GAAP EPS of -$0.89, topping the estimates by $0.23. The revenue jumped 98.3% YoY to $22.21 million, which beat the estimates by $1.37 million.
Follow Ouster Inc.
Follow Ouster Inc.
3. NuScale Power Corporation (NYSE:SMR)
Latest QTR YoY Revenue Growth: 118.8%
Number of Hedge Fund Holders: 14
NuScale Power Corporation (NYSE:SMR) is an Oregon-based company that is engaged in the designing and development of small, light water, and modular nuclear reactors. NuScale Power Corporation (NYSE:SMR) is a subsidiary of Fluor Enterprises, Inc.
Over the last three months, 3 Wall Street analysts covered NuScale Power Corporation (NYSE:SMR), and 2 kept a Buy rating on the stock. As of the December 22 market close, the average price target of $11.17 represented an upside of 240.55%.
On November 8, NuScale Power Corporation (NYSE:SMR) posted its third-quarter earnings result with revenue of $7 million, which jumped 118.8% YoY. The company ended the quarter with cash and equivalents of $196.6 million.
Follow Nuscale Power Corp
Follow Nuscale Power Corp
2. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Latest QTR YoY Revenue Growth: 62.5%
Number of Hedge Fund Holders: 15
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is an Illinois-based company that was established after Xeris Pharmaceuticals, Inc. acquired Strongbridge Biopharma plc in 2021. The company is involved in the development of novel technology platforms for developing and commercializing stable injectable and infusible drug formulations.
On November 9, Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) announced its third-quarter earnings with a GAAP EPS of -$0.09, topping the analysts’ estimates by $0.03. The revenue grew 62.5% YoY to $48.32 million, surpassing the estimates by $7.24 million.
On November 13, H.C. Wainwright lowered the price target on Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)’s stock to $5.50 from $6 and maintained a Buy rating on the shares.
According to Insider Monkey’s database, hedge fund sentiment was positive toward Xeris Biopharma Holdings, Inc. (NASDAQ:XERS). In the third quarter, 15 hedge funds were bullish on the stock, compared to 11 funds in the previous quarter. Timothy P. Lynch’s Stonepine Capital owned 5.9 million company shares worth $11 million, making it the top investor in the company.
Follow Xeris Biopharma Holdings Inc.
Follow Xeris Biopharma Holdings Inc.
1. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Latest QTR YoY Revenue Growth: 5,120%
Number of Hedge Fund Holders: 18
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a California-based company that develops treatments for immune-mediated dermatological diseases and conditions.
On November 29, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced that its roflumilast cream for seborrheic dermatitis received FDA approval. Called Zoryve, the company expects to launch the cream by the end of January 2024.
For the third quarter, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) posted its earnings result with a GAAP EPS of -$0.73, which beat the estimates by $0.15. The revenue of $38.1 million surpassed the estimates by $7.28 million, an increase of more than 5,000% YoY.
In the third quarter, 18 hedge funds held a stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)’s stock, compared to 17 in the previous quarter. With 5.034 million shares worth $26,733 million, David Rosen’s Rubric Capital Management was the biggest stakeholder in the company.
Follow Arcutis Biotherapeutics Inc. (NASDAQ:ARQT)
Follow Arcutis Biotherapeutics Inc. (NASDAQ:ARQT)
You can also look at the 11 Best Shipping Stocks That Pay Dividends and the Stagflation Definition: 11 Best Stagflation Stocks To Buy.
Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
